Weight-loss drug developer Metsera raises $275 million in US IPO
(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
The high cost of weight loss: How patients are fighting for access to breakthrough medications
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
The best exercises to do while taking weight loss drugs
If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...
GlobalData on MSN14h
Beta Bionics raises $204m to kickstart medtech IPO season
Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...